Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985023 | PMC |
| http://dx.doi.org/10.1016/j.jcot.2019.12.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new species of Gray, 1827 (Squamata, Gekkonidae) from Yunnan Nangunhe National Nature Reserve, China.
Zookeys
January 2025
Kunming Natural History Museum of Zoology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China.
A new forest-dwelling species of the group is described from southwestern Yunnan Province, China. Phylogenetically, it was recovered as the sister species of , with a genetic distance of 9.2% in the ND2 gene.
View Article and Find Full Text PDFUnlabelled: The increased rate of anterior cruciate ligament (ACL) tears has led to a greater number of revisions. Revision surgery can be performed in one or two stages. Single-stage revision ACL reconstruction (ssRACLR) may be performed when prior tunnels can be re-used or bypassed whereas a two-stage procedure is indicated when bone grafting of dilated tunnels prior to revision is necessary.
View Article and Find Full Text PDFCemdomespib Therapy Slows the Progression of Neuromuscular Weakness and Demyelination in the R75W-Connexin 32 Animal Model of Charcot-Marie-Tooth 1X Disease.
ACS Pharmacol Transl Sci
January 2025
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, Kansas 66045, United States.
Mutations in connexin 32 (Cx32) are a common cause of Charcot-Marie-Tooth 1X (CMT1X) disease, an inherited peripheral neuropathy characterized by progressive neuromuscular weakness and demyelination. There are no approved pharmacologic therapies for CMT1X, and identifying new treatments that slow the onset and severity of neuromuscular decline may aid disease management. Cemdomespib is an orally bioavailable small molecule that improved demyelination and neuromuscular junction (NMJ) morphology in mice lacking Cx32 expression.
View Article and Find Full Text PDFInduced membrane technique for aseptic recalcitrant nonunion of the femur and tibia: Bone union and deformity correction outcomes.
J Clin Orthop Trauma
February 2025
Orthopaedic and Trauma Surgery Department, Hospital de Alta Complejidad Cuenca Alta, RP6 Km 92.5 PC 1814, Cañuelas, Buenos Aires, Argentina.
Introduction: Aseptic recalcitrant nonunion (ARNU) of the femur and tibia is an entity in which the absence of bony union, misalignment, and limb length discrepancies (LLD) coexist. Currently, the management of these cases lacks consensus. This study aimed to describe the bone union rate and deformity correction outcomes in patients with ARNU of the femur or tibia treated with the Induced Membrane Technique (IMT).
View Article and Find Full Text PDFAssessing Avascular Necrosis Risk and Outcomes After Open Reduction for Developmental Dysplasia of the Hip in Children.
Cureus
December 2024
General Surgery, Prince Sultan Military Medical City, Riyadh, SAU.
Background Avascular necrosis (AVN) of the femoral head is a serious complication after surgical treatment of developmental dysplasia of the hip (DDH). The main objective of this study is to identify the incidence of AVN and to define AVN risk factors. The study also aims to identify the effects of AVN and other factors on final clinical and radiological outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!